Straits Times Index
3,201.86 -3.28 (-0.10%) S&P 500
4,544.90 -4.88 (-0.11%) Dow
35,677.02 +73.92 (+0.21%) Nasdaq
15,090.20 -125.50 (-0.82%) BTC-USD
62,720.25 +1,912.46 (+3.15%) CMC Crypto 200
1,453.34 -49.70 (-3.31%)
Orphazyme A/S (OZYMF)
| Previous close | 4.1500 |
| Open | 4.1500 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 4.1500 - 4.1500 |
| 52-week range | 3.8200 - 18.1000 |
| Volume | 100 |
| Avg. volume | 1,681 |
| Market cap | 145.052M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.9920 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action - Bronstein, Gewirtz & Grossman, LLC
NEW YORK, September 06, 2021--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired (1) Orphazyme American depositary shares ("ADSs") pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted
- Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
LOS ANGELES, September 03, 2021--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
- Business Wire
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES, August 24, 2021--CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") published the results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) in the peer-reviewed Journal of Inherited Metabolic Disease (JIM
